SAN DIEGO, June 1 /PRNewswire-FirstCall/ -- Metabasis Therapeutics, Inc. announced today that it will present a poster at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday, June 4, 2006. The title of the presentation is "A Phase I/II Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MB07133 in Subjects with Unresectable Hepatocellular Carcinoma (HCC)." The study objectives were to determine the maximum tolerated dose, toxicity profile, pharmacokinetics and anti tumor activity of MB07133 in patients with unresectable HCC.
The theme of this year's meeting, held in Atlanta, Georgia June 2nd - June 4th, is "Advocating Survivorship, Clinical Science & Oncology Quality Care" and includes numerous session offerings with 27 tracks of disease-specific or oncology-related subject areas and over 4,000 abstracts submitted. Last year's ASCO meeting attracted more than 29,000 attendees from all over the world.
ASCO is a non-profit organization founded in 1964, with overarching goals of improving cancer care and prevention ensuring that all patients with cancer receive care of the highest quality. More than 23,000 oncology health care practitioners belong to ASCO, representing all oncology disciplines and subspecialties.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis Therapeutics, Inc.CONTACT: Constance Bienfait, Vice President, Investor Relations &Corporate Communications of Metabasis Therapeutics, Inc., +1-858-622-5575
Web site: http://www.mbasis.com/
